Pixel Bridge Works With Anika Therapeutics to Launch N...(Visually represent Anika as an innovativ...)

Date:8/20/2008

Visually represent Anika as an innovative leader in its markets

• Clearly articulate the company's value proposition and market differentiation

"Our goal in designing this site was to capture the energy and entrepreneurial spirit of the company, along with its long history of leadership in therapeutic technologies," said Scott Stephens, president of Pixel Bridge. "Anika has a broad range of therapies in the market and an impressive pipeline of innovative products under development. This demanded a site that was both comprehensive and easy to navigate and reflective of the company's vision for the future. The new website illustrates the company's uniqueness and we were proud to work with them on the project."

"Pixel Bridge worked with us on every step of this engagement - from concept to completion," notes Kevin Quinlan, CFO and Treasurer at Anika. "The firm's full range of capabilities made a potentially cumbersome project streamlined and relatively painless."

ABOUT ANIKA THERAPEUTICS
Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika's products include ORTHOVISC(R), a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek; HYVISC(R), a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; the ELEVESS(TM) family of aesthetic dermatology products for facial wrinkles, scar remediation and lip augmentation marketed in the U.S. by Artes Medical, Inc.; AMVISC(R), AMVISC(R) Plus, STAARVISC(TM)-II and Shellgel(TM) injectable viscoelastic HA
'/>"/>

Source: PRWeb Copyright©2008 Vocus, Inc. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Siemens and Xintek Form Joint Venture to Develop Nanotechnology-Enabled Multi-Pixel X-ray Tubes
2. WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing
3. New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
4. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
5. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
6. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
7. NIST team proves bridge from conventional to molecular electronics possible
8. Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK
9. Woodbridge Offers the Broadest Range of BioFoam(TM) Green Polyurethane Automotive Interior Applications
10. Cambridge Major Appoints Professor John Hartwig as Scientific Advisor
11. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune